Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

CABG surgery - cholesterol lowering intervention - preoperative statins


Related trials

JUPITER, 2008 - rosuvastatin vs placebo

Song, 2008 - vs

SAGE, 2007 - atorvastatin high dose vs pravastatin

METEOR, 2007 - rosuvastatin vs placebo

CORONA, 2007 - rosuvastatin vs placebo

Chello et al., 2006 - preoperative atorvastatin vs placebo

ASPEN, 2006 - atorvastatin vs placebo

SPARCL, 2006 - atorvastatin vs placebo

Patti et al., 2006 - preoperative atorvastatin vs placebo

MEGA, 2006 - pravastatin vs control

IDEAL, 2005 - atorvastatin high dose vs simvastatin

Vascular basis, 2005 - atorvastatin high dose vs lovastatin

TNT, 2005 - atorvastatin high dose vs atorvastatin

PACT, 2004 - pravastatin vs placebo

A to Z, 2004 - simvastatin vs placebo

ESTABLISH, 2004 - atorvastatin vs usual care

REVERSAL, 2004 - atorvastatin high dose vs pravastatin

HPS (sub groups), 2004 - simvastatin vs placebo

CARDS, 2004 - atorvastatin vs placebo

PACT, 2004 - pravastatin vs placebo

ASCOT, 2003 - atorvastatin vs placebo

LIPS (sub groups), 2002 - fluvastatin vs placebo

ALLHAT, 2002 - pravastatin vs usual care

PTT, 2002 - pravastatin vs usual care

PROSPER, 2002 - pravastatin vs placebo



See also:

  • All CABG surgery clinical trials
  • All clinical trials of cholesterol lowering intervention
  • All clinical trials of preoperative atorvastatin
  •  
     Patti et al. study, 2006 TRC7246 
    download pdf: preoperative atorvastatin | cholesterol lowering intervention for CABG surgery

    Treatments

    Studied treatment preoperative atorvastatin 40 mg/d, starting 7 days before operation
    Control treatment placebo

    Patients

    Patients patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of AF

    Method and design

    Randomized effectives 101 / 99 (studied vs. control)
    Blinding double blind
    Follow-up duration 30 days


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    atrial fibrillation

    35 / 101
    56 / 99
    0,61 [0,45;0,84]

    myocardial infarction (fatal and non fatal)

    3 / 101
    3 / 99
    classic 0,98 [0,20;4,74]

    All cause death

    2 / 101
    2 / 99
    classic 0,98 [0,14;6,82]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    atrial fibrillation 35 / 101 (34,7%) 56 / 99 (56,6%) 0,61 [0,45;0,84]  
    myocardial infarction (fatal and non fatal) 3 / 101 (3,0%) 3 / 99 (3,0%) 0,98 [0,20;4,74]  
    All cause death 2 / 101 (2,0%) 2 / 99 (2,0%) 0,98 [0,14;6,82]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 30 days)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 34,65% 56,57% -21,91%
    myocardial infarction (fatal and non fatal) 2,97% 3,03% -0,06%
    All cause death 1,98% 2,02% -0,04%

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in CABG surgery for preoperative statins



    Reference(s)

    TrialResults-center ID TRC7246
    Trials register # NA
    • Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.. Circulation 2006;114:1455-61
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels